helicobacter pylori infection
Conditions
Interventions
Combination of probiotics and triple therapy group:Composite probiotics: 1 probiotic per day, taken orally directly, or delivered with warm water (50ml, below 40 degrees), taken after meals
Triple use: Amoxicillin: 2g/dose, bid, take half an hour after breakfast and dinner
Clarithromycin: 0.5g/dose, bid, taken half an hour after breakfast and dinner
Rabeprazole: 20mg/dose, bid, taken half an hour before breakfast, dinner, and meals.
Bismuth quadruple combined with placebo treatment group:Placebo: 1 tablet per day, taken orally or with warm water (50ml, below 40 degrees), taken after meals
Quadruple usage: Amoxicillin: 2g/dose, bid, taken half an hour after breakfast and dinner
Rabeprazole: 20mg/dose, bid, taken half an hour before breakfast, dinner, and meals
Potassium bismuth citrate: 0.6g/dose, bid, taken half an hour before breakfast and dinner.
Dead cell combination triple therapy group:Dead cell count: 1 piece/day, taken orally or in warm water (50ml, below 40 degrees), taken after meals
Sponsors
Inner Mongolia Autonomous Region People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily sign an informed consent form; 2. No gender limit, age 18-70 years old; 3. Positive 14C urea breath test (14C-UBT), with no prior treatment for Helicobacter pylori; 4. Have not used antibiotics, bismuth or probiotic related preparations in the month prior to enrollment;
Exclusion criteria
Exclusion criteria: 1. Subjects who have previously treated Helicobacter pylori; 2. Pregnant, pregnant or lactating women; 3. Individuals who have taken antibiotics, proton pump inhibitors, H2 receptor antagonists, bismuth preparations, and certain antibacterial drugs 4 weeks prior to enrollment; 4. Patients with a history of major gastrointestinal surgery or complications such as bleeding, perforation, obstruction, and cancer; 5. Patients with a history of drug allergies or contraindications; 6. Other serious illnesses;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 14c-urea breath test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory factor detection;Functional indicators of intestinal mucosa;Intestinal flora;Oral flora;Serum metabolome;Serological indicators;gastric microbiota; | — |
Countries
China
Contacts
Public ContactYan Li
Inner Mongolia Autonomous Region People's Hospital
Outcome results
None listed